Literature DB >> 28257285

Population pharmacokinetics of vancomycin in Chinese pediatric patients
.

Taotao Liu, Chen Deng, Daohai Cheng, Tianyan Zhou, Hua Lu, Wenxing Wei, Wei Lu.   

Abstract

OBJECTIVE: This study was conducted to develop a population pharmacokinetic (PopPK) model for vancomycin and to detect the significant covariates that influence the PopPKs to facilitate individualized therapy for Chinese pediatric patients.
METHODS: Patients ≤ 10 years old who received vancomycin for ≥ 72 hours between 2007 and 2010 were analyzed using a nonlinear mixed-effects modeling approach (-NONMEM). A one-compartment model with first-order elimination was chosen to depict the data. Stepwise covariate modeling (SCM) was employed to detect significant covariates and obtain a final model. Internal validation methods, including bootstrapping and visual predictive checks (VPC), were applied to evaluate the robustness and predictive power of the final model.
RESULTS: The analysis included 54 pediatric inpatients with 128 serum concentration samples. The mean age (range) was 124.30 (1.29 - 541.4) weeks, the mean weight was 10.36 (1.4 - 33.5) kg, and the mean baseline serum creatinine (Scr) level was 0.39 (0.15 - 1.32) mg/dL. Pneumonia was the most common indication for vancomycin therapy (33.33%), followed by bacteremia (25.93%), and meningitis (22.22%). A PopPK model of vancomycin in Chinese pediatric patients was developed. Postnatal age (PNA) significantly affected the vancomycin clearance (CL) of pediatric patients, and the influence was described using the sigmoid maximum effect (E<sub>max</sub>) model. The effect of body weight (WT) on CL and volume of distribution (V) was investigated using an allometric scaling equation. The final model parameters were CL(L/h) = 11.75×[PNA<sup>0.4672</sup>/(PNA<sup>0.4672</sup>+33.3<sup>0.4672</sup>)]×(WT/70)<sup>0.75</sup>×e<sup>0.362</sup> and V(L) = 54.49×WT/70×e<sup>0.6711</sup>. The model evaluation results suggested robustness and good predictability of the final model.
CONCLUSION: A PopPK model of vancomycin for Chinese pediatric patients was developed in this study. The significant covariates distinguished in the final model can provide helpful information to facilitate individualized therapy for Chinese pediatric patients.
.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28257285     DOI: 10.5414/CP202835

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  6 in total

1.  Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.

Authors:  Erin Chung; Jonathan Sen; Priya Patel; Winnie Seto
Journal:  Clin Pharmacokinet       Date:  2021-05-18       Impact factor: 6.447

2.  Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function.

Authors:  Chanika Chuphan; Waroonrat Sukarnjanaset; Thanyawee Puthanakit; Thitima Wattanavijitkul
Journal:  J Pediatr Pharmacol Ther       Date:  2022-07-06

3.  An Ensemble Model for Prediction of Vancomycin Trough Concentrations in Pediatric Patients.

Authors:  Xiaohui Huang; Ze Yu; Shuhong Bu; Zhiyan Lin; Xin Hao; Wenjun He; Peng Yu; Zeyuan Wang; Fei Gao; Jian Zhang; Jihui Chen
Journal:  Drug Des Devel Ther       Date:  2021-04-14       Impact factor: 4.162

4.  Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia.

Authors:  Xiangjun Fu; Liangmo Lin; Li Huang; Li Guo
Journal:  Biopharm Drug Dispos       Date:  2021-10-26       Impact factor: 1.831

5.  Modeling Approach to Optimizing Dose Regimen of Vancomycin for Chinese Pediatric Patients with Gram-Positive Bacterial Infections.

Authors:  Kai Shen; Yaxin Fan; Minjie Yang; Yuancheng Chen; Jinhao Tao; Guoping Lu; Hong Zhang; Qiwei Huang; Jing Zhang
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

6.  The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients.

Authors:  Jihui Chen; Xiaohui Huang; Shuhong Bu; Xiaoxiao Chen; Jia Zhou; Xinzhu Liu; Xiaowen Guo; Lixia Li; Jian Zhang
Journal:  Pharmacol Res Perspect       Date:  2021-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.